NAD + Tirzepatide: Safety & Clinical Evidence

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD (nicotinamide adenine dinucleotide) and tirzepatide target different metabolic pathways, and combining them may be discussed by patients seeking comprehensive metabolic support. However, no large clinical trials have specifically examined this combination, making provider guidance essential before starting either therapy.

Understanding your individual metabolic profile—including genetic predispositions in GLP-1 and metabolic regulation pathways—can help you and your provider make more informed decisions about whether combining these therapies aligns with your health goals and safety profile.

What NAD Does and How It Differs from Tirzepatide

NAD is a coenzyme essential for cellular energy production and mitochondrial function. It supports sirtuins, NAD-dependent enzymes involved in cellular repair and longevity pathways. Tirzepatide, by contrast, is a GLP-1 and GIP receptor agonist that regulates appetite, blood glucose, and metabolic rate through hormonal signaling.

While both may improve metabolic markers, they work through distinct biological mechanisms. NAD supplementation aims to restore cellular energy capacity, whereas tirzepatide acts on gut hormones. This difference means potential interactions are pharmacokinetic (drug metabolism) rather than direct pathway overlap, but medical evaluation is still necessary.

Mechanism Comparison: Cellular vs. Hormonal Metabolic Action

Understanding how these therapies differ helps clarify why combining them requires careful consideration. The table below outlines their primary mechanisms, target tissues, and metabolic endpoints.

Therapy	Primary Mechanism	Target Tissue	Metabolic Endpoint
NAD Supplementation	Restores mitochondrial coenzyme pools; activates sirtuins and PARPs	Mitochondria; neurons; muscle	Cellular energy; oxidative stress reduction
Tirzepatide	Dual GLP-1/GIP receptor agonism	Pancreatic beta cells; GI tract; CNS appetite centers	Insulin secretion; appetite suppression; glucose control
Interaction Risk	Indirect: shared metabolic load on liver metabolism	Hepatic CYP3A4 pathway	Potential altered bioavailability if NAD affects absorption
Clinical Evidence	NAD studies (aging, neuro, mitochondrial disease); tirzepatide RCTs (weight, glucose)	Separate patient populations	No dedicated co-administration trials published

Current Clinical Evidence on NAD and Tirzepatide Co-Use

No published randomized controlled trials directly assess NAD and tirzepatide together. Separate bodies of evidence support each therapy independently: tirzepatide shows robust weight loss and glycemic control in SURMOUNT and SURPASS trials; NAD studies focus on mitochondrial disease, neurodegenerative conditions, and aging biomarkers.

The absence of safety data does not mean combination is contraindicated, but it does mean shared decision-making with a healthcare provider is critical. Observational reports from practitioners combining these therapies are limited and not yet systematized in peer-reviewed literature.

Safety Considerations and Who Should Discuss This Combination

Tirzepatide carries known risks including nausea, pancreatitis risk assessment, and thyroid concerns (black-box warning for medullary thyroid carcinoma history). NAD supplementation is generally well-tolerated but may cause flushing and has minimal long-term safety data in high-dose protocols. Combining them increases the number of metabolic variables your provider must monitor.

This combination may be most relevant for individuals with metabolic dysfunction, fatigue linked to mitochondrial impairment, or weight loss resistance despite optimal GLP-1 dosing. However, only a qualified healthcare provider can assess whether your kidney function, liver metabolism, medication list, and medical history support this approach safely.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1R signaling (rs6923761), GIPR function (rs1800437), and metabolic regulation genes like MC4R and FTO. These genetic markers can support a more informed conversation with your provider about whether tirzepatide is a strong fit for your metabolic profile before considering additional therapies like NAD.

The genetic test reveals predispositions in peptide metabolic pathways, not exact medication response or NAD-tirzepatide interaction risk. However, understanding your baseline GLP-1 receptor genetics can help your provider personalize tirzepatide dosing and timing, which is important context if you are also considering NAD supplementation.

Combining this genetic insight with your current metabolic bloodwork (glucose, lipids, liver function, pancreatic enzymes) and your provider's clinical assessment creates a more complete picture for deciding whether NAD and tirzepatide are appropriate together for your health goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.